Non-Small-Cell Lung Cancer
Conditions
Keywords
adenocarcinoma, non-adenocarcinoma
Brief summary
To evaluate Non-Small Cell Lung Cancer (NSCLC) patients clinical profile and the outcome after treatment with Gefitinib in Pulmonary Oncology Outpatient Clinic Dr. Soetomo General Hospital, Surabaya, Indonesia.
Detailed description
Primary Objective: To determine the efficacy of Gefitinib in NSCLC patient harboring a positive EGFR mutation. Secondary Objective: To evaluate the subjective response of NSCLC patients harboring a positive EGFR mutation who treated with Gefitinib. Safety Objective: To evaluate the safety and tolerability of Gefitinib in NSCLC patient harboring a positive EGFR mutation.
Interventions
None listed
Sponsors
Dr. Soetomo General Hospital
Study design
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
16 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* NSCLC based on histopathologic examination * Adenocarcinoma and/or nonadenocarcinoma based on histology examination * Clinical stadium stage IIIB and IV * Age 16-70 years old * Received gefitinib as therapy * At least completed 2 (two) data sets of RECIST 1.1 evaluations during the study period from January 2013 until July 2015
Exclusion criteria
* Missing data of any variables of the treatment outcomes in the medical record
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS (Progression Free Survival) | through study completion, in average of 1 year | Progression Free Survival (PFS) as defined by RECIST 1.1 or attending physician's clinical judgement of clinical progression state |
| Overall Survival (OS) | through study completion, in average of 1 year | Overall Survival (OS) as defined by the date of death certificate given by the attending physician or by other government officials |
Countries
Indonesia
Contacts
Primary ContactLaksmi Wulandari, MD, PhD
Backup ContactAnna Febriani, MD
Outcome results
None listed